Probucol effects on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II

Aim. To investigate effects of a hypolipidemic drug with antioxidant action probucol on electrophysiological parameters of the heart in patients with ischemic heart? disease (IHD), stable angina (SA), hyperlipoproteinemia (HL P) and diabetes mellitus (DM) type II. Material and methods. The trial entered 45 IHD patients (11 males and 37 fe males) aged 47-73 years with SA functional class II and III (39.4 and 60.6% , respectively), secondary HLP (mean group total cholesterol 6.5+/-0.17 mmo l/l), DM type II (mean fast glucose 7.7+/-1.8 mmol/l) and obesity (mean bod y mass index 29.7+/-2.2 kg/m(2)). Transesophageal pacing of the left ventri cle was conducted in all the patients before probucol treatment and 18 hour s, 1 month and 3 months after it. Results, Probucol (a single dose 500 mg) significantly reduced the time of recovery of sinus node function. Three months of probucol administration in a dose 1000 mg/day enhanced pacemaker activity of the sinus node. Conclusion. In addition to a beneficial effect on lipid metabolism (a decre ase of total cholesterol by 13.4%, LDLP cholesterol by 15.2%, triglycerides by 15.8%), probucol enhanced pacemaker activity of the sinus node. This ma kes it perspective in patients with sinus node dysfunction. Caution is nece ssary in prescribing probucol to patients with supraventricular tachycardia caused by re-entry mechanism.